The Role of Anti-TNFα Therapy in the Amelioration of Disease Burden in Patients with Refractory Rheumatoid Arthritis

Abdul-Elah Kamel, Laith; Mohammed Sheet, Madha; Nasser Farhood, Jamal

	The Role of Anti-TNFα Therapy in the Amelioration of Disease Burden in Patients with Refractory Rheumatoid Arthritis
Al-Mustansiriyah Journal for Pharmaceutical Sciences
Article 1, Volume 14, Issue 1, 2014, Pages 14-22
Authors
Laith Abdul-Elah Kamel; Madha Mohammed Sheet; Jamal Nasser Farhood
Abstract
Abstract: To evaluate the changes in anti cyclic citrullinated peptide (Anti-CCP) antibodies, rheumatoid factor (RF), interleukins 17 and 10 (IL-17 and IL-10), high sensitivity C- reactive protein (hs CRP) and T regulatory cells (Treg) count following an anti TNF-α biological agent (etanercept) therapy in patients with rheumatoid arthritis. Refractory rheumatoid arthritis patients who failed treatment with DMARDs (disease modifying anti rheumatic drugs) were treated with etanercept for three months. Serum and blood samples were tested before and after therapy for six markers including ACCP, RF, IL- 10, IL 17, hs CRP, and Treg cell. A significant dropping down in the serum level of ACCP, RF and hs CRP was documented 3 months after etanercept therapy. On the other hand a non- significant elevation in IL-10 serum level and peripheral blood Treg cell count, as well as a non significant dropping down in the serum level of IL-17 were also reported. Etanercept is a successful anti-TNF-α therapy in refractory RA patients for the first three months of the course therapy as indicated by clinical improvement and amelioration in 6 disease activity markers. Key words: rheumatoid arthritis, IL-17, etanercept, Treg, TNF-α
Keywords
Key Words; etanercept; Treg; TNF

Statistics Article View: 60 PDF Download: 25